Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 6
MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ensure coverage criteria for MS medications, and they also consider the factors that influence their decision-making process when selecting therapies for patients with relapsing multiple sclerosis.
EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
EP: 4.Examining Key Unmet Needs in Multiple Sclerosis
EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
Now Viewing
EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment
EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
EP: 13.Multiple Sclerosis: Looking Toward the Future
Video content above is prompted by the following questions:
- The most recent guidelines for MS treatment are from 2018. Why is it important for an update to them?
- Payers often utilize not only pivotal trials when creating or updating coverage criteria for medications used to treat MS, but also other clinical studies and treatment guidelines. What role do guidelines, such as the MS Guidelines, play in updating or creating coverage criteria?
- Which patient factors weigh into your decision making for MS therapies for patients with relapsing multiple sclerosis?
Related Videos
Related Content
